Furthermore, it addresses the FDA’s communications Using the applicant, the retention of documents that assist the SE report, confidentiality of the SE report, how an applicant can amend or withdraw an SE report, how an applicant may possibly transfer possession of an SE report back to a new applicant and electronic submission with the SE report